Prime Medicine (PRME) Current Assets (2021 - 2026)
Prime Medicine's (PRME) quarterly Current Assets came in at $137.9 million in Q1 2026, down 15.8% YoY from $163.8 million in Q1 2025, and down 23.94% on a QoQ basis from $181.3 million in Q4 2025.
Prime Medicine (PRME) Current Assets (2021 - 2026) Analysis & Trends
Prime Medicine (PRME) has 6 years of Current Assets data on file, last reported at $137.9 million in Q1 2026.
- Quarterly Current Assets fell 15.8% year-over-year to $137.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $137.9 million (down 15.8% YoY) and the FY2025 annual result came in at $181.3 million, down 14.44% from the prior year.
- Current Assets eased to $137.9 million in Q1 2026, from $181.3 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $296.6 million in Q4 2022 to a low of $121.3 million in Q2 2025.
- A 5-year average of $195.1 million and a median of $184.5 million in 2023 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2023 — Current Assets slumped 51.8% — and 2024, when it soared 48.2%.
- Tracing PRME's Current Assets over 5 years: stood at $296.6 million in 2022, then tumbled by 51.8% to $143.0 million in 2023, then soared by 48.2% to $211.9 million in 2024, then retreated by 14.44% to $181.3 million in 2025, then retreated by 23.94% to $137.9 million in 2026.
- The last three Current Assets figures came in at $137.9 million (Q1 2026), $181.3 million (Q4 2025), and $231.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Prime Medicine | 558.48 Mn | 558.48 Mn | - | 96.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 96.80 Mn |
| Mar 31, 2026 | 137.89 Mn |
| Dec 31, 2025 | 181.29 Mn |
| Sep 30, 2025 | 231.41 Mn |
| Jun 30, 2025 | 121.29 Mn |
| Mar 31, 2025 | 163.77 Mn |
| Dec 31, 2024 | 211.89 Mn |
| Sep 30, 2024 | 246.07 Mn |
| Jun 30, 2024 | 170.80 Mn |
| Mar 31, 2024 | 217.65 Mn |
| Dec 31, 2023 | 142.98 Mn |
| Sep 30, 2023 | 184.53 Mn |
| Jun 30, 2023 | 218.49 Mn |
| Mar 31, 2023 | 253.50 Mn |
| Dec 31, 2022 | 296.62 Mn |
| Sep 30, 2022 | 148.85 Mn |
| Dec 31, 2021 | 270.58 Mn |